Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Agios Pharmaceuticals (AGIO) over the last 13 years, with Dec 2024 value amounting to $39,000.

  • Agios Pharmaceuticals' Gains from Investment Securities rose 291.18% to $65,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 180.84%. This contributed to the annual value of $39,000 for FY2024, which is 107.05% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Gains from Investment Securities is $39,000, which was up 107.05% from -$553,000 recorded in FY2023.
  • In the past 5 years, Agios Pharmaceuticals' Gains from Investment Securities ranged from a high of $578,000 in FY2021 and a low of -$553,000 during FY2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $39,000 (2024), whereas its average is -$61,000.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 267.07% in 2023, then surged by 107.05% in 2024.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Gains from Investment Securities stood at $336,000 in 2020, then surged by 72.02% to $578,000 in 2021, then plummeted by 42.73% to $331,000 in 2022, then crashed by 267.07% to -$553,000 in 2023, then skyrocketed by 107.05% to $39,000 in 2024.